Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
624 Longitudinal scRNAseq profiling of PBMCs from melanoma patients treated with anti-CTLA4 or anti-PD1/CTLA4 combination elucidates mechanisms of immunotherapy resistance
Compose a Response to This Article
Other responses
No responses have been published for this article.
